A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign...
Benign Prostatic HyperplasiaThis is a 24 week study evaluating the effects of botulinum toxin Type A on semen quality in patients with signs and symptoms of Benign Prostatic Hyperplasia (BPH).
ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management...
Prostatic HyperplasiaAcute Urinary RetentionTo assess the efficacy of alfuzosin 10mg OD in the management of acute urinary retention associated with BPH. To assess the safety of alfuzosin in this population and health care consumption.
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Lower Urinary Symptoms Due to Benign...
Benign Prostatic HyperplasiaThe purpose of this study was to determine the safety and effectiveness of different doses of botulinum toxin Type A in treating lower urinary tract symptoms due to benign prostatic hyperplasia.
ALF-ONE : ALFuzosin ONcE Daily
Prostatic HyperplasiaThe aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis...
HyperplasiaChronic Renal FailureThe purpose of this study is to determine the effect of recipient vein pretreatment of edifoligide (E2F Decoy), compared to placebo, on graft/recipient vein stenosis in polytetrafluoroethylene (PTFE) vascular access grafts placed for hemodialysis at 6 months after enrollment.
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)
Prostate DiseaseBPH2 moreMulti-center, prospective randomized dosing and safety research study. A maximum of 150 men will be enrolled in the study. Qualifying patients will receive one of three possible doses of the study drug. Symptoms will be evaluated before treatment, and then 1-week, 1-month, 3-months, and 6-months following treatment.
Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets
Congenital Adrenal HyperplasiaThis study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH).
A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients...
Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)This is an open-label, single-arm, prospective interventional study to assess the tolerability and efficacy of Harnalidge® OCAS® 0.4 mg in Taiwan patients who are unsatisfied with tamsulosin 0.2 mg for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms...
Prostatic HyperplasiaStudy to evaluate the symptomatic relief afforded by tamsulosin hydrochloride capsules in patients with signs and symptoms of benign prostatic hyperplasia (BPH). Additionally to provide primary care physicians experience with the use of tamsulosin hydrochloride capsules 0.4 mg daily for the treatment of BPH
Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects
Prostatic HyperplasiaThis will be a single center, open-label, single dose, randomized and 2-way crossover study in healthy Japanese male subjects under fasting conditions. The study will be conducted to determine the bioequivalence between dutasteride capsules manufactured at GSK (test product) and dutasteride capsule manufactured at Catalent (reference product) in healthy Japanese male subjects. Subjects will have a screening visit within 30 days prior to the first dose of study treatment, two treatment periods separated by 28-days washout period, a re-visit 10-14 days after the second dose for the first follow-up and a second follow up via telephone 50-54 days after the second dose. The total duration of the study will be approximately 15 weeks from screening to the second follow up.